GlassScriptPhysician profile
Joel N Saltzman
NPI 1578582227
$2,519.03
in general payments reported to CMS, 2019-2025
47 companies · $296 in 2025
The $296 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,406 · 2020: $409 · 2021: $230 · 2024: $178 · 2025: $296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $296 · Education: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $295.78 |
| Education | $177.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $355.36 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $279.00 | 2019-2025 | |
| Incyte Corporation | $122.66 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $113.37 | 2019 | |
| Pfizer INC. | $110.92 | 2019-2024 | |
| Janssen Biotech, INC. | $100.60 | 2019-2021 | |
| Comsort, INC | $100.00 | 2019 | |
| Seagen INC. | $91.29 | 2019-2024 | |
| Astellas Pharma US INC | $75.11 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $72.38 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $70.01 | 2019 | |
| Exelixis INC. | $69.38 | 2019-2021 | |
| Tesaro, INC. | $65.33 | 2019 | |
| Lilly USA, LLC | $57.80 | 2019-2020 | |
| Shionogi INC | $52.34 | 2019 |
Show all 45 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Saltzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.